B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.
Saved in:
| Title: | B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer. |
|---|---|
| Authors: | Kielbik A; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany., Bahlinger V; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tuebingen, Tuebingen, Germany., Schürch CM; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tuebingen, Tuebingen, Germany., Barcena ML; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany., Vakhrusheva O; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany., Thomas A; Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany., Tsaur I; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany., Heitmann JS; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tuebingen, a Partnership Between DKFZ and University Hospital Tuebingen, Tuebingen, Germany., Hagelstein I; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tuebingen, a Partnership Between DKFZ and University Hospital Tuebingen, Tuebingen, Germany. |
| Source: | ImmunoTargets and therapy [Immunotargets Ther] 2026 May 01; Vol. 15, pp. 577364. Date of Electronic Publication: 2026 May 01 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101606565 Publication Model: eCollection Cited Medium: Print ISSN: 2253-1556 (Print) Linking ISSN: 22531556 NLM ISO Abbreviation: Immunotargets Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
